MA45921A - Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine. - Google Patents

Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.

Info

Publication number
MA45921A
MA45921A MA045921A MA45921A MA45921A MA 45921 A MA45921 A MA 45921A MA 045921 A MA045921 A MA 045921A MA 45921 A MA45921 A MA 45921A MA 45921 A MA45921 A MA 45921A
Authority
MA
Morocco
Prior art keywords
connective tissue
tissue fixation
improving connective
sclerostine
antibodies
Prior art date
Application number
MA045921A
Other languages
English (en)
Inventor
Michael S Ominsky
Stavros Thomopoulos
Original Assignee
Amgen Inc
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Univ Washington filed Critical Amgen Inc
Publication of MA45921A publication Critical patent/MA45921A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MA045921A 2016-08-08 2017-08-07 Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine. MA45921A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662372124P 2016-08-08 2016-08-08

Publications (1)

Publication Number Publication Date
MA45921A true MA45921A (fr) 2019-06-19

Family

ID=59656213

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045921A MA45921A (fr) 2016-08-08 2017-08-07 Procédé d'amélioration de la fixation du tissu conjonctif à l'aide d'anticorps anti-sclérostine.

Country Status (9)

Country Link
US (1) US20190185556A1 (fr)
EP (1) EP3496744A1 (fr)
JP (1) JP2019527710A (fr)
KR (1) KR20190037261A (fr)
CN (1) CN110214021A (fr)
AU (1) AU2017310412A1 (fr)
CA (1) CA3032348A1 (fr)
MA (1) MA45921A (fr)
WO (1) WO2018031454A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
KR20200034748A (ko) * 2017-07-27 2020-03-31 지앙수 헨그루이 메디슨 컴퍼니 리미티드 Sost 항체 약학적 조성물 및 그의 용도
EP3787645A4 (fr) * 2018-05-02 2022-06-01 Ortheus, Inc. Systèmes et méthodes pour la modulation locale de la voie de signalisation wnt
GB201810746D0 (en) * 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
KR102327010B1 (ko) * 2019-03-29 2021-11-16 서울대학교병원 재조합 부갑상선 호르몬을 포함하는 회전근 개 봉합 후 치유용 조성물
WO2021030179A1 (fr) * 2019-08-12 2021-02-18 Amgen Inc. Formulations d'anticorps anti-sclérostine
US12310928B2 (en) 2020-11-16 2025-05-27 University Of Utah Research Foundation Enthesis healing
EP4408884A4 (fr) * 2021-09-30 2025-04-23 Mereo Biopharma 3 Limited Méthodes d'utilisation d'anticorps anti-sclérostine dans le traitement de l'ostéogenèse imparfaite

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
EP0088046B1 (fr) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipides en phase aqueuse
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (fr) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Composition pharmaceutique contenant de l'urokinase
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
US8696875B2 (en) 1999-10-08 2014-04-15 Applied Materials, Inc. Self-ionized and inductively-coupled plasma for sputtering and resputtering
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
CN1835974A (zh) 2003-06-16 2006-09-20 细胞技术研究与发展公司 对硬化素特异的抗体和用于增加骨矿化的方法
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
EP2114435A1 (fr) 2007-02-02 2009-11-11 Novartis AG Modulateurs de partenaires de liaison de la sclérostine pour traiter des troubles liés aux os
EP2131860B1 (fr) 2007-03-20 2013-12-18 Eli Lilly & Company Anticorps antisclérostine
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
MX2010004761A (es) 2007-11-02 2010-05-19 Novartis Ag Moleculas y metodos para modular la proteina relacionada con el receptor de lipoproteina de baja densidad 6 (lrp6).
WO2010100179A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Système de gel autoformé pour administration de médicament à libération lente
WO2010100200A2 (fr) 2009-03-05 2010-09-10 Novartis Ag Préparation d'anticorps lyophilisée
WO2010115932A1 (fr) 2009-04-08 2010-10-14 Novartis Ag Combinaison pour traitement de perte osseuse
WO2010130830A2 (fr) 2009-05-15 2010-11-18 Ablynx N.V. Séquences d'acides aminés dirigées contre la sclérostine et polypeptides comprenant ces dernières pour le traitement de maladies et de pathologies des os
JP6770312B2 (ja) * 2012-07-05 2020-10-14 ユセベ ファルマ ソシエテ アノニム 骨疾患の治療
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
CN110214021A (zh) 2019-09-06
CA3032348A1 (fr) 2018-02-15
AU2017310412A1 (en) 2019-02-21
EP3496744A1 (fr) 2019-06-19
AU2017310412A8 (en) 2019-03-07
US20190185556A1 (en) 2019-06-20
KR20190037261A (ko) 2019-04-05
JP2019527710A (ja) 2019-10-03
WO2018031454A1 (fr) 2018-02-15

Similar Documents

Publication Publication Date Title
EP3702459A4 (fr) Procédé d'amélioration de l'expression de l'hémoglobine foetale
EP3319688A4 (fr) Procédé et système pour améliorer la stimulation d'un tissu excitable
EP3684318A4 (fr) Système& procédé d'instrument de réglage chiropratique
EP3399989A4 (fr) Anticorps anti-lag3 et fragments de fixation à l'antigène
EP3387623A4 (fr) Système et procédé de production de modèles informatisés de structures à l'aide de techniques de reconstruction et d'extraction de géométrie
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
EP3294143A4 (fr) Systèmes et procédés pour l'imagerie de structures de tissu biologique
EP3294108A4 (fr) Procédé et système de stérilisation à la vapeur d'endoscopes
EP3365063A4 (fr) Procédé de notation d'un échantillon comprenant un tissu tumoral
EP3706725A4 (fr) Processus pour la préparation de tapinarof
EP3475707A4 (fr) Test sanguin pour exclure par dépistage la présence d'amyloïde et de la maladie d'alzheimer
EP3355907A4 (fr) Protéines thérapeutiques bispécifiques pour la réparation de tissus
EP3852631A4 (fr) Procédé d'imagerie
EP3695433A4 (fr) Procédé de préparation d'échantillon de section transversale
EP3488782A4 (fr) Programme d'aide au diagnostic
HUE058921T2 (hu) Bisz-kolin-tetratiomolibdát wilson-betegség kezelésére
EP3958217C0 (fr) Procédé de déformation de vêtement basé sur la déformation de laplace du corps humain
EP3804853A4 (fr) Procédé de préparation d'indoxacarb s
EP3734268A4 (fr) Procédé simplifié de quantification d'anticorps monoclonaux
EP3397131A4 (fr) Système et procédé de fourniture d'assistance au cours d'une chirurgie en présence d'une déformation des tissus
EP3859332A4 (fr) Procédé de dosage d'hémoglobine glyquée (%)
EP3518845A4 (fr) Appareil d'élimination de tissu
EP3835417A4 (fr) Procédé pour la culture de tissu cancéreux ou de tissu analogue à du tissu cancéreux
EP3454765A4 (fr) Instrument d'ablation de tissu
EP3564218A4 (fr) Procédé de préparation d'acide 1,4,7,10-tétraazacyclododécane-1,4,7,10-tétraacétique